Search the Newsreel

Price-Driven Insight from (ASND) for Rule-Based Strategy

This article provides a price-driven insight for Ascendis Pharma A/s (ASND), highlighting divergent sentiment across all time horizons and an exceptional 27.2:1 risk-reward setup. It details institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis to guide potential trading …

Ascendis Pharma A/S Revenue Breakdown – NASDAQ:ASND

Ascendis Pharma A/S (NASDAQ: ASND) generated a total revenue of $845.80 million last year, with its Pharmaceutical segment being the largest contributor at $812.73 million. A significant portion of this revenue, $616.64 million, came from the United States market. This indicates a substantial increase …

ASND|Ascendis Pharma A/S|Price:256.235|Chg%:+2.375

This article provides a detailed company profile for Ascendis Pharma A/S (ASND), a Denmark-based pharmaceutical company. It outlines their business scope, manufacturing products for growth hormone deficiency, endocrinology, CNS disorders, infectious diseases, and diabetes, and lists key financial data and market performance metrics. The …

Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns

Artisan Small Cap Fund reduced its position in Ascendis Pharma A/S (ASND) during Q2 2026 due to lawsuit concerns, despite maintaining conviction in the company's long-term prospects. The fund noted mixed recent results for ASND, with revenues below expectations but EPS exceeding estimates, and …

Ascendis Pharma A/S (ASND) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Ascendis Pharma A/S (ASND), highlighting its current earnings forecast score of 9.00, which ranks 15th in the Biotechnology & Medical Research industry. Analysts have a strong buy rating for the stock with an average price target of …

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $275

Morgan Stanley has reiterated its Buy rating on Ascendis Pharma A/S (ASND.US) and increased its price target to $275. This continued positive outlook suggests the firm sees strong potential for the company's valuation growth.

Ascendis Pharma A/S (ASND) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for Ascendis Pharma A/S (ASND), showing its current trading price and daily percentage change. It also includes sections for analyst ratings, although none are currently available, and mentions the lack of earnings information for the company. …

ASND5566766 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Ascendis Pharma A/S bond with the identifier ASND5566766. It details that the bond has a current coupon rate of 2.25% and its next interest payment is scheduled for October 1, 2026. The profile offers an overview …

(ASND) Price Dynamics and Execution-Aware Positioning

This article analyzes Ascendis Pharma A/s (NASDAQ: ASND) price dynamics, highlighting a weak near

ASND5566766 Bond Profile — Key Metrics

This article provides key metrics for the ASND5566766 bond issued by Ascendis Pharma A/S. It details the bond's coupon rate, maturity date, issuer information, and other crucial financial data. The bond is a 2.25% bond maturing on April 1, 2028.

Price to earnings forward of Ascendis Pharma A/S – DUS:A710

This article provides the "Price to earnings forward" metric for Ascendis Pharma A/S (DUS:A710) on the Dusseldorf Stock Exchange. It is a financial data point presented by TradingView, with data sourced from ICE Data Services and FactSet. The page is concise and focuses solely …

Ascendis Pharma (ASND) grants 14,060 employee warrants at $265.57

Ascendis Pharma A/S granted 14,060 warrants to employees on July 14, 2026, with an exercise price of US $265.57 per share. These warrants have a vesting schedule where 25% vest after one year, and the remaining 75% vest monthly over 36 months, subject to …

Ascendis Pharma AS (ASND) extends four-week biotech rally to 30.4%

The weekly setup remains active, but lighter turnover tempers the strength behind the advance.

Ascendis Pharma’s 30% month reaches the high, but July participation cools to 0.8x

Ascendis Pharma closed at $274.50, only 0.1% below its 52-week high, after a four-week advance of 30.4%. The Trend backdrop remains active, but lighter volume and a wide Fair Value premium keep the weekly read balanced rather than emphatic.

Ascendis Pharma (ASND) Joins Multiple Russell Indexes

Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position

Ascendis Pharma (ASND) Profit Swing To €10.2 EPS Tests Earnings Quality Concerns

Ascendis Pharma Reports First Quarter 2026 Financial Results

Earnings call transcript: Ascendis Pharma Q1 2026 beats EPS forecast By Investing.com

We Might See A Profit From Ascendis Pharma A/S (NASDAQ:ASND) Soon

Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth

Ascendis Pharma Revenue Growth Meets Regulatory Countdown For TransCon CNP

Ascendis Pharma misses Q4 revenue estimates despite strong YORVIPATH sales

Oppenheimer Increases Price Target for Ascendis Pharma (ASND) Am

Ascendis Pharma (ASND) Stock Price, News & Analysis

Ascendis Pharma Q3 2024: Revenue Growth & Partnerships

Ascendis Pharma A/S (ASND) stock price, news, quote and history